| CLINICAL STUDY |
Treating fibrotic diseases Endothelin is overexpressed in two forms of interstitial lung disease: idiopathic pulmonary fibrosis and pulmonary fibrosis due to scleroderma. Endothelin blockade with BoSentan may provide a new treatment opportunity. Currently, pulmonary fibrosis is treated with drugs, such as corticosteroids or gamma-interferon, that have never been shown to be effective in clinical trials and have no proven effect on disease progression or survival rates. Trials with BoSentan in the indic ations of idiopathic pulmonary fibrosis for BUILD-1 (Bosentan Use in Interstitial Lung Disease) and pulmonary fibrosis secondary to scleroderma (BUILD-2) were initiated in 2003. Results are expected in late 2005 and early 2006. |
| UPDATE | 03.04 |
| COMPANY | This data is not available for free |
|
Want more information ? Interested in the hidden information ? Click here and do your request. |